Anticoagulation orale: attitudes pratiques

Niederer, A; Wuillemin, WA; Moerloose, Philippe de

doi:10.4414/fms.2001.04125

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study focused on the four DOACs available in Switzerland: edoxaban, rivaroxaban, apixaban, and dabigatran. Additionally, we examined the two VKAs marketed in Switzerland: acenocoumarol which is the VKA of choice in French-speaking Switzerland, and phenprocoumon, which is widely prescribed in the German-speaking areas ( Niederer et al, 2001 ; Bochatay et al, 2016 ).…”

Section: Methodsmentioning

confidence: 99%

Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland

Coumau,

Gaspar,

Terrier

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Toxicity or treatment failure related to drug-drug interactions (DDIs) are known to significantly affect morbidity and hospitalization rates. Despite the availability of numerous databases for DDIs identification and management, their information often differs. Oral anticoagulants are deemed at risk of DDIs and a leading cause of adverse drug events, most of which being preventable. Although many databases include DDIs involving anticoagulants, none are specialized in them.Aim and method: This study aims to compare the DDIs information content of four direct oral anticoagulants and two vitamin K antagonists in three major DDI databases used in Switzerland: Lexi-Interact, Pharmavista, and MediQ. It evaluates the consistency of DDIs information in terms of differences in severity rating systems, mechanism of interaction, extraction and documentation processes and transparency.Results: This study revealed 2’496 DDIs for the six anticoagulants, with discrepant risk classifications. Only 13.2% of DDIs were common to all three databases. Overall concordance in risk classification (high, moderate, and low risk) was slight (Fleiss’ kappa = 0.131), while high-risk DDIs demonstrated a fair agreement (Fleiss’ kappa = 0.398). The nature and the mechanism of the DDIs were more consistent across databases. Qualitative assessments highlighted differences in the documentation process and transparency, and similarities for availability of risk classification and references.Discussion: This study highlights the discrepancies between three commonly used DDI databases and the inconsistency in how terminology is standardised and incorporated when classifying these DDIs. It also highlights the need for the creation of specialised tools for anticoagulant-related interactions.

show abstract

Section: Methodsmentioning

confidence: 99%

Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland

Coumau,

Gaspar,

Terrier

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Prevention of cardiovascular diseases

Vakrilova Becheva,

Kirkova-Bogdanova,

Ivanova

et al. 2023

PHAR

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are socially significant diseases due to high morbidity and loss of people of working age. In Bulgaria, they are the leading cause of mortality among the population and are a consequence of the effect of cardiovascular risk factors. The draft of the National Health Strategy (NHS) 2021–2030 reports on their wide distribution, as well as on the insufficient knowledge, skills and motivation for their prevention and control. The purpose of this review is to address the prevention of cardiovascular disease, which is a significant problem worldwide. Prevention goals for patients with established cardiovascular disease and those at high risk include smoking cessation, healthy eating, physical activity, and lowering body mass index. There are various methods that are part of health promotion to reduce CVD risks. These methods include motivational interviewing, non-pharmacological means, the use of certain medications for CVD prevention, as well as physical activity. Strategies for effective primary prevention refer to engaging the patient to change their lifestyle and identifying risk factors, while secondary prevention is aimed at activities to detect the disease early and to slow down its progression. It is necessary to create a strategy for timely preventive actions with a view to preventing the negative influence of risk factors and improving people‘s heart health.

show abstract

Anticoagulation orale: attitudes pratiques

Cited by 2 publications

References 0 publications

Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland

Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland

Prevention of cardiovascular diseases

Contact Info

Product

Resources

About